This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Slapak, C. A. Articles by Levy, S. B. Search for Related Content PubMed PubMed Citation Articles by Slapak, C. A. Articles by Levy, S. B.

Sequential Emergence of Distinct Resistance Phenotypes in Murine Erythroleukemia Cells under Adriamycin Selection: Decreased Anthracycline Uptake Precedes Increased P-Glycoprotein Expression¹

Division of Hematology/Oncology, Department of Medicine, New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts 02111

First-step Adriamycin (doxorubicin)-resistant mutants of the murine erythroleukemia cell line PC4 were cloned from Adriamycin-containing (10 ng/ml) methylcellulose at a frequency of 3 x 10^-4. They demonstrated 1.6- to 2.4-fold stable resistance to Adriamycin. Most were cross-resistant to etoposide, but not to vincristine, and were without enhanced expression of mdr genes, which code for P-glycoproteins. Two different murine erythroleukemia cell lines, PC4 and C7D, were passaged in suspension culture into stepwise increasing amounts of Adriamycin. No high-level resistant mutants were isolated de novo; cells initially displayed low-level resistance to Adriamycin and etoposide. Two stepwise doublings of the drug concentration were needed before PC4 cells acquired vincristine resistance, but there was no detectable overexpression of mdr or a change in anthracycline uptake. In a subsequent doubling of Adriamycin concentration, the cells showed a further increase in resistance to all three drugs and now a decreased anthracycline accumulation. However, there was still no detectable increase in mdr expression as judged by Northern analysis of poly(A)+ enriched RNA and Western blot analysis of membrane proteins. Only after a fourth doubling of Adriamycin concentration did the cells demonstrate enhanced expression of mdr and P-glycoprotein. Equivalent mutants of C7D were selected, but generally at lower Adriamycin concentrations. Verapamil partially lowered resistance, but failed to restore parental susceptibility in any mutant; it caused an increased uptake in those mutants showing decreased anthracycline accumulation, including those that did not overexpress mdr. This study demonstrated different resistance phenotypes among mutants appearing spontaneously under stepwise drug selection; mutants with vincristine resistance and decreased anthracycline uptake preceded those associated with over-expression of P-glycoprotein.

¹ This work was supported in part by the Arnold D. Imperatore Research Scholarship of the National Leukemia Association and USPHS Fellowships 5T32CA09429 and F32-CA08774 (C. A. S.).

² To whom requests for requests should be addressed, at Division of Hematology/Oncology, Department of Medicine, New England Medical Center, 750 Washington Street, Boston, MA 02111.

Received 11/10/89. Accepted 9/17/90.

This article has been cited by other articles:

				C. Friesen, M. Uhl, U. Pannicke, K. Schwarz, E. Miltner, and K.-M. Debatin DNA-Ligase IV and DNA-Protein Kinase Play a Critical Role in Deficient Caspases Activation in Apoptosis-resistant Cancer Cells by Using Doxorubicin Mol. Biol. Cell, August 1, 2008; 19(8): 3283 - 3289. [Abstract] [Full Text] [PDF]

				O. Legrand, G. Simonin, A. Beauchamp-Nicoud, R. Zittoun, and J.-P. Marie Simultaneous Activity of MRP1 and Pgp Is Correlated With In Vitro Resistance to Daunorubicin and With In Vivo Resistance in Adult Acute Myeloid Leukemia Blood, August 1, 1999; 94(3): 1046 - 1056. [Abstract] [Full Text] [PDF]

				L. A. Hazlehurst, N. E. Foley, M. C. Gleason-Guzman, M. P. Hacker, A. E. Cress, L. W. Greenberger, M. C. De Jong, and W. S. Dalton Multiple Mechanisms Confer Drug Resistance to Mitoxantrone in the Human 8226 Myeloma Cell Line Cancer Res., March 1, 1999; 59(5): 1021 - 1028. [Abstract] [Full Text] [PDF]